肝动脉化疗栓塞联合调强放疗治疗原发性肝癌的临床疗效
Clinical Analysis of Transcatheter Arterial Chemoembolization Combined with Intensity Modulated Radiotherapy Therapy for Patients with Primary Hepatic Carcinoma
-
摘要: 目的 评价肝动脉化疗栓塞 (TACE) 联合调强放疗 (IMRT) 治疗肝癌的疗效.方法 符合入组条件的原发性肝癌 (PHC) 患者68例随机分为治疗组 (TACE联合IMRT) 34例和对照组 (单纯TACE) 34例, 对照组采用单纯TACE治疗.治疗组先行23次TACE治疗, 在介入治疗治疗后24周后行放射治疗.结果 治疗组近期有效率为82.4%显著高于对照组61.8% (P<0.05) ;治疗组与对照组1 a、2 a生存率分别为76.5%、55.9%、和58.9%、32.4%, 2组生存率比较差异有统计学意义 (P<0.05) .2组均无严重毒副反应发生.结论TACE联合IMRT治疗原发性肝癌较单纯介入治疗明显提高治疗效果, 患者耐受性良好, 无严重的远期并发症.Abstract: Objective To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) in combination with intensity modulated radiotherapy (IMRT) in treatment of primary hepatic carcinoma (PHC) .Methods All 68 patients with PHC were randomized into treatment group (TACE plus IMRT) and control group (TACE alone) , with 34 cases in each group.Patients in the control group were treated with interventional therapy alone.Patients in the treatment group were treated with interventional therapy (transcatheter arterial chemoembolization) plus radiotherapy.Treatment group patients firstly received 2 to 3 times interventional therapy, then followed by radiotherapy with 2 to 4 week interval.Results The short-term efficacy was 82.4% in treatment group which was significantly higher than 61.8% in control group (P<0.05) .The survival rate was 76.5% in 1 year and55.9% in 2 years in treatment group, 58.9% and 32.4% in control group respectively.The difference between 2group was statistical significance (P<0.05) No serious toxicities were observes in the patients of the two groups.Conclusion The results suggest that the treatment effect of TACE plus IMRT is better than interventional therapy alone for patients with primary Hepatic carcinoma, and has well tolerance and fewer adverse reactions.
-
[1] [1]HUBNER M, MCCORMACK L, CLAVIEN P A.Surgical therapy of liver tumors:resection vs ablation[J].Schweiz Rundsch Med Prax, 2005, 94 (33) :1255. [2] [2]KOKUDO N, MAKUUCHI M.Current role of portal vein embolization/hepatic artery chemoembolizatior[J].Surg Clin North Am, 2004, 8 (2) :643. [3]扬秉辉, 夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 200l, 9 (6) :324. [4]周蔼斌, 周俊平.细胞因子及其信号通路在放射性肝损伤发病中的作用研究进展[J].实用肝脏病杂志, 2016, 19 (6) :766-769. [5]黄丹丹, 罗杨坤, 杨家林.晚期肝癌调强适形放射治疗的疗效及预后分[J].西部医学, 2011, 23 (4) :621-623. [6]孙燕, 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社, 1996:102-140. [7] [7]HEE C P, JINSIL S, KWANG H H, et al.Dose-response relationship in radiotherapy for hepatocellular carcinoma[J].Int J Radia Oncol Biol Phys, 2002, 54 (1) :150-155. [8] [8]CHANG Y, YANG Z Y, LI G L, et al.Correlations between radiation dose in bone marrow and hematological toxicity in patients with cervical cancer:a comparison of3DCRT, IMRT, and rapid ARC[J].Int J Gynecol Cancer, 2016, 26 (4) :770-776. [9]王家平, 章树乔.介入联合γ刀治疗原发性肝癌的疗效分析[J].实用放射学杂志, 2009, 25 (3) :405-406. [10]耿长新, 曾昭冲, 王吉耀, 等.多烯紫杉醇在体内对肝癌的抑制和放疗增敏及其作用[J].中华肝病杂志, 2005, 13 (1) :60-61. [11]张立洁, 彭泉, 芦东徽, 等.三维适形放疗联合TACE治疗肝癌并发门静脉癌栓疗效的Meta分析[J].实用肝脏病杂志, 2015, 18 (3) :254-257. 期刊类型引用(7)
1. 柳彬，李志颖. 调强放疗联合肝动脉化疗栓塞术治疗原发性肝癌患者的效果. 中国民康医学. 2022(03): 30-32 . 
百度学术2. 张英，郭敬，冯涛，周燕，黄瑶，邓小凤，郑璐. 医护患共同决策模式在原发性肝癌患者围手术期的应用. 昆明医科大学学报. 2021(08): 177-180 . 本站查看3. 吴红平，赵虑达，叶妙桂. 介入联合放射治疗与介入治疗原发性大/巨大肝癌临床疗效的比较研究. 临床合理用药杂志. 2020(18): 156-157 . 百度学术4. 陈一平，王彩虹，林清锋，洪金省，陈仲武，陈金梅. 肝动脉化疗栓塞联合放疗治疗中晚期原发性肝细胞癌的近期疗效. 福建医科大学学报. 2020(06): 417-419 . 百度学术5. 廖云忠，关秀丽，彭小萍，刘振波. TACE术中应用吉西他滨对原发性肝癌疗效及血清甲胎蛋白的影响. 解放军医药杂志. 2019(03): 39-42 . 百度学术6. 谷雪，赵娟，付文娟，孙芳初，张海利. 调强放射治疗对不宜手术且其他局部治疗无效的原发性大肝癌患者的临床疗效及预后生存分析. 癌症进展. 2018(01): 81-83+91 . 百度学术7. 田希凤. IMRT联合TACE治疗中晚期肝癌患者疗效及安全性观察. 山西职工医学院学报. 2018(03): 84-86 . 百度学术其他类型引用(1)
-
点击查看大图
计量
- 文章访问数: 2690
- HTML全文浏览量: 945
- PDF下载量: 88
- 被引次数: 8
下载:
